Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis

BACKGROUND: Long-acting injectable cabotegravir, a drug taken every 2 months, has been shown to be more effective at preventing HIV infection than daily oral tenofovir disoproxil fumarate and emtricitabine, but its cost-effectiveness in a high-prevalence setting is not known. We aimed to estimate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Jamieson, Lise, Johnson, Leigh F, Nichols, Brooke E, Delany-Moretlwe, Sinead, Hosseinipour, Mina C, Russell, Colin, Meyer-Rath, Gesine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708606/
https://www.ncbi.nlm.nih.gov/pubmed/36356603
http://dx.doi.org/10.1016/S2352-3018(22)00251-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708606/
https://www.ncbi.nlm.nih.gov/pubmed/36356603
http://dx.doi.org/10.1016/S2352-3018(22)00251-X

Ejemplares similares